More positive data for Novo’s Ozempic

The phase IIIa trial PIONEER 5 has shown Novo Nordisk’s oral diabetes treatment Ozempic (semaglutide) to be effective at weight loss and reducing blood sugar in diabetes patients with renal impairment. The trial involved 324 patients with type II diabetes and kidney damage and measured blood sugar levels in patients on semaglutide versus placebo and demonstrated a statistically significant and superior improvement in both blood sugar levels and weight loss.

Novo Nordisk EVP and chief science officer, Mads Krogsgaard Thomsen, said: “The results from PIONEER 5 showed that oral semaglutide is efficacious and has a solid safety profile in people with type 2 diabetes and moderate renal impairment, thereby further expanding the solid clinical profile of oral semaglutide. Renal impairment is a serious diabetes complication and people with this condition have limited oral anti-diabetic treatment options, and if approved oral semaglutide represents an efficacious new solution for these people.”